| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Pharmadrug Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.011 |
| 52 Week High | CA$0.08 |
| 52 Week Low | CA$0.0035 |
| Beta | 2.91 |
| 1 Month Change | -65.63% |
| 3 Month Change | -24.66% |
| 1 Year Change | 214.38% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| G11 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | -0.3% |
| 1Y | 214.4% | -26.4% | 2.8% |
Return vs Industry: G11 exceeded the German Pharmaceuticals industry which returned -26.4% over the past year.
Return vs Market: G11 exceeded the German Market which returned 2.8% over the past year.
Price Volatility
| G11 volatility | |
|---|---|
| G11 Average Weekly Movement | 63.3% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: G11's share price has been volatile over the past 3 months.
Volatility Over Time: G11's weekly volatility has decreased from 454% to 63% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Robert Steen | www.pharmadrug.ca |
Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It also imports and distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates Super Smart, an entity building to vertically integrated elevate the use of functional mushrooms and psilocybin mushrooms.
Pharmadrug Inc. Fundamentals Summary
| G11 fundamental statistics | |
|---|---|
| Market cap | €2.12m |
| Earnings (TTM) | -€8.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs G11 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G11 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$13.20m |
| Earnings | -CA$13.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -120.5% |
How did G11 perform over the long term?
See historical performance and comparison